Outcomes in COVID-19 adintrevimab studies
Outcomes in adintrevimab studies. mAb use may create new variants that spread globally
Focosi . mAb use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape
Choudhary .
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 studies
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Effect extraction pre-specified (most serious outcome)
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 mortality results
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
84%
0.16 [0.02-1.34]
hosp.
1/752
6/728
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
80%
0.20 [0.01-4.15]
hosp.
0/175
2/176
Tau2 = 0.00, I2 = 0.0%, p = 0.047
Prophylaxis
83%
0.17 [0.03-0.98]
1/927
8/904
83% lower risk
All studies
83%
0.17 [0.03-0.98]
1/927
8/904
83% lower risk
2 adintrevimab COVID-19 hospitalization results
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.047
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 serious outcomes
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Effect extraction pre-specified (most serious outcome)
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
70%
0.30 [0.16-0.56]
symp. case
12/752
39/728
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
75%
0.25 [0.07-0.88]
symp. case
3/175
12/176
Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Prophylaxis
71%
0.29 [0.16-0.51]
15/927
51/904
71% lower risk
All studies
71%
0.29 [0.16-0.51]
15/927
51/904
71% lower risk
2 adintrevimab COVID-19 case results
c19 early
Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 Randomized Controlled Trials
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Effect extraction pre-specified (most serious outcome)
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 RCT mortality results
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 peer reviewed studies
c19 early
Tau2 = 0.00, I2 = 0.0%, p = 0.48
Effect extraction pre-specified (most serious outcome)
Favors adintrevimab
Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+
EVADE PrEP Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PrEP Ison (DB RCT)
50%
0.50 [0.13-1.99]
death
3/1,001
6/1,001
EVADE PrEP Ison (DB RCT)
84%
0.16 [0.02-1.34]
death
1/752
6/728
EVADE PrEP Ison (DB RCT)
84%
0.16 [0.02-1.34]
hosp.
1/752
6/728
EVADE PrEP Ison (DB RCT)
70%
0.30 [0.16-0.56]
symp. case
12/752
39/728
EVADE PEP Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
EVADE PEP Ison (DB RCT)
80%
0.20 [0.01-4.15]
death
0/240
2/241
EVADE PEP Ison (DB RCT)
80%
0.20 [0.01-4.15]
hosp.
0/175
2/176
EVADE PEP Ison (DB RCT)
75%
0.25 [0.07-0.88]
symp. case
3/175
12/176
Adintrevimab COVID-19 outcomes
c19 early
Favors adintrevimab
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
